1.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

2.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

3.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

4.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

5.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

6.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

7.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

8.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

9.

Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.

1.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

2.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

3.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

4.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

5.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

6.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

7.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

8.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

9.

Comparison of the mutation spectrum and association with pre and post treatment lipid measures of children with heterozygous familial hypercholesterolaemia (FH) from eight European...

1.

The effect of financial and educational incentives on rational prescribing:A state-space approach

2.

The effect of financial and educational incentives on rational prescribing:A state-space approach

1.

LLT prescriptions of patients with definite or probable FH, at baseline and at month-6 of follow-up a .

2.

LLT prescriptions of patients with definite or probable FH, at baseline and at month-6 of follow-up a .

1.

Statin intensity of patients with definite or probable FH, at baseline and at month-6 of follow-up a .

2.

Statin intensity of patients with definite or probable FH, at baseline and at month-6 of follow-up a .

1.

Demographic and clinical characteristics and comorbidities of patients with definite, probable, possible or unlikely FH, at baseline a .

2.

Demographic and clinical characteristics and comorbidities of patients with definite, probable, possible or unlikely FH, at baseline a .

1.

Flowchart of study subjects.

2.

Flowchart of study subjects.

1.

Lipid panel of study subjects at baseline.

2.

Lipid panel of study subjects at baseline.

1.

LLT change status of patients with definite or probable FH at 6-month of follow-up.

2.

LLT change status of patients with definite or probable FH at 6-month of follow-up.

1.

Demographic characteristics and comorbidities of patients with probable or definite FH at baseline.

2.

Demographic characteristics and comorbidities of patients with probable or definite FH at baseline.